The Role of Some Hematological Parameters in Juvenile Systemic Lupue Erythematosus

NCT06227559 | Unknown

• 1 other identifier: Juvenile systemic lupus
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

Juvenile systemic lupus erythematosus is an autoimmune disorder with multisystem involvement, leading to inflammatory damage to the joints, kidney, central nervous system, and hematopoietic system. Although the prevalence rate of juvenile systemic lupus erythematosus in a developing country is not known, as per literature the female-to-male ratio rises from 4.5 : 1 in adolescence to 8--12 : 1 in adult-onset patients. \- The full mechanism of SLE is still unknown however, production of autoantibodies and immune complex deposition with subsequent infiltration of neutrophils, hyper-activation of B and T cells, reduced ability of immune complexes and apoptotic cell clearance, and defects in multiple immune regulatory networks, are central to organ inflammation and subsequent damage in SLE. Systemic lupus erythematosus goes on with organ involvements by remission and relapses.

Conditions

Systemic Lupus Erythematosus

Outcome Measures

Primary Outcomes (4)

• Measure the absolute neutrophil-to-absolute lymphocyte ratio (NLR).

  Measuring the absolute neutrophil-to-absolute lymphocyte ratio (NLR) by automated complete blood count ( 2 ml of venous blood will be obtained from the patients )

  Baseline

• Measure the mean platelet volume (MPV).

  Measuring the mean platelet volume (MPV) by automated complete blood count ( 2 ml of venous blood will be obtained from the patients )

  Baseline

• Measure the platelet count-to-absolute lymphocytes ratio (PLR).

  Measuring the platelet count-to-absolute lymphocytes ratio (PLR) by automated complete blood count ( 2 ml of venous blood will be obtained from the patients )

  Baseline

• Measuring the monocyte distribution width (MDW)}.

  Measuring the monocyte distribution width (MDW)} by automated complete blood count ( 2 ml of venous blood will be obtained from the patients )

  Baseline

Eligibility Criteria

• Age: Up to 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

this study will include all patients diagnosed and followed up as jSLE, and will be consecutively recruited from the inpatient and outpatient clinic of Immunology and rheumatology department at Assuit University children's hospital

You may qualify if:

• Age at enrollment ≤18 years old.
• Both sexes
• The Patients should be diagnosed as jSLE, according to 2019 European league against rheumatism (EULAR)/ American college of rheumatology (ACR) SLE classification criteria, or the previous ACR 1997 SLE classification criteria.

You may not qualify if:

• Patients with autoimmune diseases other than j SLE
• Patients not fulfilling the criteria for diagnosis of SLE
• Active infections.
• Malignancies.
• Lymphoproliferative disorders.
• Hematologic diseases
• Hepatosplenic diseases and diabetic nephropathy

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Lupus Erythematosus, Systemic

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 17, 2023
• First Posted: January 29, 2024
• Study Start: February 1, 2024
• Primary Completion: April 1, 2024
• Study Completion: June 1, 2024
• Last Updated: January 29, 2024

Record last verified: 2024-01